Repligen Corporation (RGEN)

From the record

Repligen Corporation's filings since 2017 show 3 warning events of 2 kinds: a warning not to rely on past financial statements (8-K item 4.02, the latest 2024-09-18); a late-report notice (Form NT 10-K or NT 10-Q, 2 times, the latest 2025-03-03) (its current reports).

From the record

Repligen Corporation's 10 filed years say what it did: revenue went from $105 million in fiscal 2016 to $738 million in fiscal 2025, up 24.3% a year; it rose in 8 of 9 years; the deepest fall was 21% from fiscal 2022 to fiscal 2023; net income was positive in 9 of 10 of those years (its annual reports).

From the record

Over the 3 fiscal years to 2025-12-31, Repligen Corporation's diluted share count shrank about 0.5% a year, and dividends and buybacks returned about 4% of its operating cash flow over 3 years (its filed statements). Its officers and directors filed 25 sales (16 under scheduled 10b5-1 plans) and 0 purchases of their own stock on the open market in the year to 2026-10-08 (their Form 4 filings).

From the record

Return on equity: in the fiscal year ended 2025-12-31, Repligen Corporation earned about 2 cents of profit for every dollar of shareholders' money, and gross profitability: its products earned about 13 cents per dollar of everything the company owns (revenue less the cost of revenue). Leverage: it owed about 29 cents per dollar of assets, and net share issuance: its share count grew 1.1% over the year (the filed statements).

From the record

Repligen Corporation's standing among 102 graded names in its industry family: revenue of $738 million in fiscal 2025 ranks in the top 11% by size; a net margin of 6.6% ranks in the top 18%; revenue growth of -2.7% a year over the last 3 filed years ranks in the bottom 35% (its annual reports).

From the record

Repligen Corporation's leadership, from its insiders' filings and its current reports: the chief executive on the record is Loeillot, Olivier (Chief Executive Officer, as filed), filing under that title since 2024-09-04, 2.2 years (bottom 26% of its family); the 15 officers and directors filing in the last fifteen months have been on the record a median of 5.7 years (top 42%); 5 officer or director changes were reported on Form 8-K since 2023-11-13, against the 15 people in charge now (top 30%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

From the record

Repligen Corporation's room to grow, from the newest filed statements (fiscal 2025): cash of $566 million against debt of $542 million leaves 0.8% of its assets as net cash, bottom 7% of its family; cash from operations less capital spending is 12.7% of revenue (top 14%); a gross margin of 52.3% (bottom 31%); research spending of 7.3% of revenue (bottom 5%) (its annual report).

From the record

Repligen Corporation's growth drivers, from the filed years to fiscal 2025: revenue grew -2.7% a year over the last three filed years against 24.3% over all 10, slowing (bottom 25% of its family); the newest year grew 16.4% (top 50%); research spending grew 7.2% a year (top 38%); capital spending grew -34.8% a year (bottom 47%) (its annual reports). Repligen Corporation reported 6 product lines in fiscal 2025: Filtration Products at $403 million (55%), Chromatography Products at $153 million (21%), Proteins Products at $97 million (13%), and 3 more; 5 of 6 grew against the year before (its annual report).

From the record

Repligen Corporation's newest year against its own record: revenue of $738 million in fiscal 2025 came in 30.8% above the $564 million its prior three years' pace pointed to (top 36% of its family); net income of $49 million against a prior three-year average of $65 million (bottom 29%); a net margin of 6.6% against 8.3% before (bottom 33%) (its annual reports).